Cobra Biologics successfully completes key milestone in CombiGene’s epilepsy project CG01 with delivery of first DNA plasmid
Production method of plasmids developed and first plasmid produced for gene therapy drug candidate aimed at treating drug resistant focal epilepsy
Keele, UK and Lund, Sweden, 2 April 2020: Cobra Biologics (“Cobra”), an international CDMO for biologics and pharmaceuticals, and CombiGene AB (publ) (“CombiGene”), a leading Nordic gene therapy company, today announced the successful production and delivery, by Cobra, of the first DNA plasmid required to produce CombiGene’s gene therapy drug candidate CG01, developed for the treatment of drug-resistant focal epilepsy.
The production of compounds for a novel gene therapy depends on cultivated and modified cells, and is therefore a more complex process than for traditional drug candidates. For the vital compounds of CG01, Cobra Biologics has finalised production and delivery of the first of three key plasmids, enabling the downstream processes to be initiated. In addition to these plasmids, a specific type of cell, which Cobra is also producing, acting as the ‘factory’ to produce the CG01 compound is necessary.
After the production of the plasmids for CG01, and the successful transfer of the production process from CGT Catapult to Cobra, an engineering run will be initiated, whereby the entire production process will be tested. Material from this engineering run will be used in the toxicity and biodistribution tests that are planned.
Karin Agerman, Chief Research and Development Officer, CombiGene: “The successful production and delivery of the first of three vital plasmids is a major milestone in our collaboration with Cobra Biologics, and in the CG01 project. We look forward to a continued successful partnership working together to bring this treatment to epilepsy patients.”
Peter Coleman, Chief Executive, Cobra Biologics: “This is an exciting step in the progression of the CG01 project, in which we are proud to be taking such a key role. Following the announcement of this collaboration in October last year, we have demonstrated the strength in our experience and capabilities to respond quickly, yet accurately, to support CombiGene in bringing CG01 closer to market, sooner.”
About Cobra Biologics www.cobrabio.com
Cobra Biologics is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply to an international customer base.
Each of Cobra’s GMP approved facilities are tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market.
As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries.
CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.